hydroxyproline has been researched along with calcipotriene in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Goffe, BS; Guzzo, C; Katz, HI; Lazarus, G; Lowe, NJ; Pincus, SH | 1 |
| Criado, G; Del Rey, MJ; Faré, R; Pablos, JL; Usategui, A | 1 |
1 trial(s) available for hydroxyproline and calcipotriene
| Article | Year |
|---|---|
Topical calcipotriene has no short-term effect on calcium and bone metabolism of patients with psoriasis.
Topics: Administration, Cutaneous; Adult; Alkaline Phosphatase; Bone and Bones; Bone Density; Calcitriol; Calcium; Densitometry; Dermatologic Agents; Double-Blind Method; Female; Humans; Hydroxyproline; Hypercalcemia; Male; Middle Aged; Ointments; Parathyroid Hormone; Pharmaceutical Vehicles; Psoriasis | 1996 |
1 other study(ies) available for hydroxyproline and calcipotriene
| Article | Year |
|---|---|
Topical vitamin D analogue calcipotriol reduces skin fibrosis in experimental scleroderma.
Topics: Administration, Topical; Animals; Bleomycin; Calcitriol; Collagen; Cytokines; Dermatologic Agents; Disease Models, Animal; Female; Fibrosis; Humans; Hydroxyproline; Interleukin-13; Mice; Mice, Inbred C3H; Scleroderma, Systemic; Skin; Thymic Stromal Lymphopoietin; Up-Regulation | 2014 |